Stereotactic hypofractionated high‐dose irradiation for stage I nonsmall cell lung carcinoma

• Published in: Cancer 2004-10, Vol.101 (7), p.1623-1631
• Main Authors: Onishi, Hiroshi, Araki, Tsutomu, Shirato, Hiroki, Nagata, Yasushi, Hiraoka, Masahiro, Gomi, Kotaro, Yamashita, Takashi, Niibe, Yuzuru, Karasawa, Katsuyuki, Hayakawa, Kazushige, Takai, Yoshihiro, Kimura, Tomoki, Hirokawa, Yutaka, Takeda, Atsuya, Ouchi, Atsushi, Hareyama, Masato, Kokubo, Masaki, Hara, Ryusuke, Itami, Jun, Yamada, Kazunari
• Format: Article
• Language: English
• Subjects: altered fractionation; dose escalation; local control; multicenter study; nonsmall cell lung carcinoma; radiotherapy; Stage I; stereotactic; survival rate
• ISSN: 0008-543X; 1097-0142
• DOI: 10.1002/cncr.20539

BACKGROUND Stereotactic irradiation (STI) has been actively performed using various methods to achieve better local control of Stage I nonsmall cell lung carcinoma (NSCLC) in Japan. The authors retrospectively evaluated results from a Japanese multiinstitutional study. METHODS Patients with Stage I NSCLC (n = 245; median age, 76 years; T1N0M0, n=155; T2N0M0, n=90) were treated with hypofractionated high‐dose STI in 13 institutions. Stereotactic three‐dimensional treatment was performed using noncoplanar dynamic arcs or multiple static ports. A total dose of 18–75 gray (Gy) at the isocenter was administered in 1–22 fractions. The median calculated biologic effective dose (BED) was 108 Gy (range, 57–180 Gy). RESULTS During follow‐up (median, 24 months; range, 7–78 months), pulmonary complications of National Cancer Institute‐Common Toxicity Criteria Grade > 2 were observed in only 6 patients (2.4%). Local progression occurred in 33 patients (14.5%), and the local recurrence rate was 8.1% for BED ≥ 100 Gy compared with 26.4% for < 100 Gy (P < 0.05). The 3‐year overall survival rate of medically operable patients was 88.4% for BED ≥ 100 Gy compared with 69.4% for < 100 Gy (P < 0.05). CONCLUSIONS Hypofractionated high‐dose STI with BED < 150 Gy was feasible and beneficial for curative treatment of patients with Stage I NSCLC. For all treatment methods and schedules, local control and survival rates were better with BED ≥ 100 Gy compared with < 100 Gy. Survival rates in selected patients (medically operable, BED ≥ 100 Gy) were excellent, and were potentially comparable to those of surgery. Cancer 2004. © 2004 American Cancer Society. Patients (n = 245) with Stage I nonsmall cell lung carcinoma (T1N0M0, n=155; T2N0M0, n=90) were treated with hypofractionated high‐dose stereotactic irradiation in 13 institutions. Local control and survival rates in selected patients (medically operable, biologic effective dose ≥ 100 gray) were excellent, and were potentially equivalent to those of surgery.